Connect Biopharma is trading at $1.24, down -5.82%, after investor disappointment that its Phase 2 asthma trial missed statistical significance on the primary Day 28 endpoint despite positive lung-function data.
- No verified company-specific announcement or late-breaking event was identified for September 22, 2026; the latest listed press release remains dated September 15.
- The broader market is only modestly lower, so the immediate pre-market catalyst remains unclear.